SK Bioscience submits request for inclusion of SKYCovione on WHO emergency use listing
08 Sep 2022 01:39pm
SKYCovione, is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize immune efficiency. - Photo: International Vaccine Institute
A
A
A
The EUL qualifies unlicensed vaccines, therapeutics and in vitro diagnostics to be made available to people affected by a public health emergency. The listing is essential for companies to participate in bids by international health agencies.
The South Korean company submitted a separate request for conditional usage approval of SKYCovione with the European Medicines Agency in July, Yonhap news agency reported.
SK Bioscience CEO, Ahn Jae Yong, said the company will take the lead in responding to the COVID-19 pandemic by promptly obtaining approval from global health regulatory agencies.
South Korea's first homegrown vaccine, SKYCovione, is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize immune efficiency. It made its market debut in South Korea last Friday. - BERNAMA
